Key result
Apixaban shows no difference in major bleeding compared to enoxaparin after gynecologic cancer surgery.
Why the study?
Enoxaparin is recommended for thromboprophylaxis after gynecologic cancer surgery, but high cost and low adherence prompted evaluation of an oral, cost-effective alternative.
Does apixaban reduce major bleeding and clinically relevant nonmajor bleeding events compared to enoxaparin in women undergoing surgery for gynecologic cancer?
RCT (n=400)
Open-label, blinded end point
1:1 ratio using an online randomizer
Yes
Does apixaban reduce major bleeding and clinically relevant nonmajor bleeding events compared to enoxaparin in women undergoing surgery for gynecologic cancer?
Oral apixaban is a safe, well-tolerated, and easier-to-use alternative to subcutaneous enoxaparin for postoperative VTE prophylaxis in gynecologic cancer surgery.
Answers are grounded in this paper and cite their sources.
Apixaban shows comparable major bleeding to enoxaparin; extends RCT evidence supporting oral VTE prophylaxis as a convenient alternative after gynecologic cancer surgery.
Importance: Current guidelines recommend a 28-day course of enoxaparin for thromboprophylaxis after surgery for gynecologic cancer. The high cost of this medication and the low adherence rates observed in prior studies provide an opportunity to benefit patients by demonstrating the safety of a more cost-effective, easier to use thromboprophylactic. Objective: To investigate the safety and efficacy of an oral treatment alternative for thromboprophylaxis in postoperative patients with gynecologic cancer. Design, Setting, and Participants: This was a patient-based, multicenter, open-label, blinded, end point, randomized clinical trial conducted May 2015 to March 2019 in outpatient and inpatient gynecologic oncology settings. Women undergoing surgery for suspected or confirmed gynecologic cancer were approached for recruitment. The trial compared rates of major bleeding and clinically relevant nonmajor bleeding events during a 90-day follow-up period in patients taking apixaban or enoxaparin for postoperative thromboprophylaxis using a modified intent-to-treat analysis. Data analysis was performed from October to December 2019. Interventions: Women were randomized to 28 days of apixaban (2.5 mg orally twice daily) or enoxaparin (40 mg subcutaneously daily). Main Outcomes and Measures: The primary outcome was major bleeding and clinically relevant nonmajor bleeding events. Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction. Results: Of 500 women recruited for the study, 400 were enrolled and randomized (median age, 58.0 years; range, 18.0-89.0 years); 204 received apixaban and 196 received enoxaparin. Treatment groups did not differ in terms of race/ethnicity, cancer stage, or surgery modality (open vs robotic). There were no statistically significant differences between the apixaban and enoxaparin groups in terms of rates of major bleeding events (1 patient [0.5%] vs 1 patient [0.5%]; odds ratio [OR], 1.04; 95% CI, 0.07-16.76; P > .99), clinically relevant nonmajor bleeding events (12 patients [5.4%] vs 19 patients [9.7%]; OR, 1.88; 95% CI, 0.87-4.1; P = .11), venous thromboembolic events (2 patients [1.0%] vs 3 patients [1.5%]; OR, 1.57; 95% CI, 0.26-9.50; P = .68), adverse events, medication adherence, or quality of life between the groups. Participant satisfaction was significantly greater in the apixaban group with regard to ease of taking the medication (186 patients [98.9%] vs 110 patients [58.8%]; OR, 0.06; 95% CI, 0.01-0.25; P < .001) and pain associated with taking the medication (4 patients [2.1%] vs 92 patients [49.2%]; OR, 9.20; 95% CI, 2.67-31.82; P < .001). Conclusions and Relevance: These findings suggest that oral apixaban is a potentially safe, less painful, and easier-to-take alternative to subcutaneous enoxaparin for thromboprophylaxis after surgery for gynecologic cancer. The efficacy of apixaban to prevent venous thromboembolic events is hypothesized as being equivalent. Trial Registration: ClinicalTrials.gov Identifier: NCT02366871.
No takes yet. Share an insight, caveat, or question.
Guntupalli et al. (2020) conducted an RCT in Gynecologic cancer undergoing surgery (n=400). Apixaban vs. Enoxaparin 40 mg subcutaneously daily was evaluated on Major bleeding events (OR 1.04, 95% CI 0.07-16.76, p=>.99). Apixaban resulted in similar rates of major bleeding compared to enoxaparin in women undergoing surgery for gynecologic cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: